 SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 GLOBE NEWSWIRE -- Harpoon Therapeutics, Inc. NASDAQ: HARP, a clinical-stage immunotherapy company developing novel T cell engagers, announced today that the preclinical data on HPN601 for the treatment of solid tumors has been accepted for oral presentation at the 35th Society for Immunotherapy of Cancer SITC annual meeting. The virtual meeting takes place November 9-14, 2020. HPN601 targets the tumor antigen EpCAM and is based on Harpoons proprietary ProTriTACTM T cell engager prodrug platform designed to enable the effective targeting of more broadly expressed tumor antigens. 